Any current/future new fundraising through debt or equity?

Management did not explicitly mention any current or planned fundraising through debt or equity during the call. Vikas Gupta stated the company has a decent cash reserve currently. They remain open to acquisitions and are actively looking for strategic inorganic opportunities. For funding such acquisitions, the company is prepared to explore appropriate funding routes as and when opportunities arise. No specific plans or timelines for raising capital through debt or equity were provided. The focus currently is on investing in new growth initiatives like medical devices, biosimilars, and CDMO b

Any current/future capex/capital investment/strategic investment?

Alkem Laboratories is investing INR 400-450 crores in their US facility to build a CDMO (Contract Development and Manufacturing Organization) business. This CDMO business is expected to incur losses this year and into early FY26 but aims to break even by FY26. The company is also entering the medical devices market, signing agreements to get technology for hip and knee replacements, targeting hospitals via distributors. There are investments being made in biosimilar and medical device businesses, contributing to increased operating expenses by approximately INR 100-110 crores every quart

Future growth expectations in sales/revenue/volumes?

Consolidated top-line growth aspiration is around 8% to 10%, driven largely by productivity growth. (Page 17) Domestic market growth is expected to be in line with the overall market, estimated at 8% to 10%. (Page 7) Chronic segment growth is catching up but is expected to be 5% to 10% lower than consolidated levels; acute segment is expected to have 10% to 20% higher productivity growth than chronic. (Page 17) Non-U.S. international business is targeted to grow at mid-teens CAGR over the next 2-3 years, through a mix of entering new countries and expanding existing markets. (Page 13) New

Future growth expectations in earnings/operating earnings/profits/EPS?

Alkem aims for consolidated top-line growth of 8% to 10%, largely driven by productivity improvements. EBITDA margin guidance remains around 18% for FY25, with operational improvement offset by investments in new growth initiatives. Gross margin expected to improve by 100-150 bps to approximately 62-62.5%. Additional EBITDA pressure of about 50 bps expected in Q3 and Q4 from new initiatives like US CDMO facility and medical devices business. Investments (INR 400-450 crores) in CDMO are expected to impact margins this year, with break-even targeted by FY26. International non-U.S. mark

Alkem Laboratories LtdQ1 FY25Pharmaceuticals & Biotechnology

Alkem Laboratories Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹5,079P/E: 26.7Market Cap: ₹60.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 4

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

Consolidated top-line growth aspiration is around 8% to 10%, driven largely by productivity growth. (Page 17)
Domestic market growth is expected to be in line with the overall market, estimated at 8% to 10%. (Page 7)
Chronic segment growth is catching up but is expected to be 5% to 10% lower than consolidated levels; acute segment is expected to have 10% to 20% higher productivity growth than chronic. (Page 17)
Non-U.S. international business is targeted to grow at mid-teens CAGR over the next 2-3 years, through a mix of entering new countries and expanding existing markets. (Page 13)
New business opportunities such as CDMO, medical devices, and OTC categories are being built and expected to be growth drivers, with some revenue impact to be seen from FY26 onward. (Pages 14 and 16)
Acute portfolio expected to improve growth from Q2 onwards after sluggishness previously. (Page 7)

Margin guidance

Category 4

Alkem aims for consolidated top-line growth of 8% to 10%, largely driven by productivity improvements.
EBITDA margin guidance remains around 18% for FY25, with operational improvement offset by investments in new growth initiatives.
Gross margin expected to improve by 100-150 bps to approximately 62-62.5%.
Additional EBITDA pressure of about 50 bps expected in Q3 and Q4 from new initiatives like US CDMO facility and medical devices business.
Investments (INR 400-450 crores) in CDMO are expected to impact margins this year, with break-even targeted by FY26.
International non-U.S. markets are expected to grow at mid-teens over 2-3 years, aiding margin and profit growth.
Chronic portfolio growth to catch up, with acute productivity expected 10-20% higher than consolidated levels.
New segments like medical devices and OTC expected to be significant future growth drivers, though meaningful revenue is a few quarters away.

See what Alkem Laboratories Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Management did not explicitly mention any current or planned fundraising through debt or equity during the call.
Vikas Gupta stated the company has a decent cash reserve currently.
They remain open to acquisitions and are actively looking for strategic inorganic opportunities.
For funding such acquisitions, the company is prepared to explore appropriate funding routes as and when opportunities arise.
No specific plans or timelines for raising capital through debt or equity were provided.
The focus currently is on investing in new growth initiatives like medical devices, biosimilars, and CDMO business using existing resources.

Order book

The transcript provided does not explicitly mention details about the current or expected order book or pending orders for Alkem Laboratories Limited. The discussion primarily focuses on: - Productivity and top-line growth aspirations (8%-10% growth) - EBITDA margin guidance and impacts of new initiatives and investments - Market growth and segment-wise growth (chronic vs. acute productivity) - Business segments including international markets, medical devices, US generics, and CDMO investments - Impact of supply chain issues and resolutions - Regulatory and litigation updates affecting product launches No specific commentary or quantitative disclosure is made regarding order book status or pending orders in the provided transcript.

See what Alkem Laboratories Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Alkem Laboratories is investing INR 400-450 crores in their US facility to build a CDMO (Contract Development and Manufacturing Organization) business.
This CDMO business is expected to incur losses this year and into early FY26 but aims to break even by FY26.
The company is also entering the medical devices market, signing agreements to get technology for hip and knee replacements, targeting hospitals via distributors.
There are investments being made in biosimilar and medical device businesses, contributing to increased operating expenses by approximately INR 100-110 crores every quarter beyond Q1.
Alkem is exploring inorganic growth opportunities and remains open to acquisitions to drive strategic expansion, supported by their decent cash reserves.
Incremental spends related to new initiatives are expected to impact EBITDA margin by about 50-100 basis points, with some costs starting mainly from Q3 onwards.

Track Alkem Laboratories Ltd — get its next earnings analysis in your feed

How does Alkem Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAlkem Laboratories Ltd

Rev 4Mar 4

See where Alkem Laboratories Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Alkem Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Alkem Laboratories Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Alkem Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Alkem Laboratories Ltd Q1 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Alkem Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Alkem Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season